Q-linea

About Us

Q-linea is an innovative infection diagnostics company that primarily develops instruments and disposables for rapid and reliable infection diagnostics. Our vision is to help save lives by ensuring antibiotics continue to be an effective treatment for future generations. Q-linea develops and delivers preferred solutions for healthcare providers, enabling them to accurately diagnose and treat infectious disease in the shortest possible time. The company’s lead product ASTar® is a fully automated instrument for antibiotic susceptibility testing (AST), giving a susceptibility profile within six hours directly from a positive blood culture. For more information, please visit www.qlinea.com.

Links

Q-linea

Pick a time period -

Tags ( Active)

All Regulatory Non-Regulatory

INTERIM REPORT 1 JANUARY – 31 MARCH 2019

Fri, May 03, 2019 07:30 CET

Final version of ASTar shows favourable results and garners positive receptionQuarter: January–March 2019 · Net sales amounted to SEK 0.4 million (0.3). · The operating result totalled SEK -36.7 million (-23.9). · The company reported a loss after tax of SEK -36.3 million (-24.0). · Earnings per share amounted to SEK -1.59 (-2.06). · Cash flow from operating activities totalled SEK -41.0 million (-25.7). · At 31 March 2019, cash and cash equivalents amounted to SEK 20.6 million (354.4). Short-term investments in fixed-income funds totalled SEK 290.0 million (150.0) and

There are no items matching the current filter

There are no more items matching the current filter

Back to top

Share

About Us

Links

INTERIM REPORT 1 JANUARY – 31 MARCH 2019